Dr Joël Richard is currently Senior Vice President, Peptides Development in IPSEN (France). He is globally leading all the IPSEN pharmaceutical development activities of small molecules and peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinologie and Neurology. Dr Richard has more than 28 years of experience in chemistry and biopharmaceutical R&D, including several global senior positions in various Biotech and Pharma companies, such as:
– Vice President, Drug Product Development in IPSEN (France) (2008-2011),
– Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008),
– Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004),
– COO at Mainelab (France), a drug delivery company he co-founded with Jean-Pierre Benoit, which was specialized in developing solvent-free processes for protein delivery systems (1999-2004).
Since 1996, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. Dr Richard graduated from Ecole Normale Supérieure (Cachan, 1985). He has got a PhD in Materials Science (University of Paris VI, 1987) and “Habilitation à Diriger les Recherches” in Chemistry (University of Bordeaux I, 1993). He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields (colloids and interfaces, drug delivery, supercritical fluids, protein formulations, nanoparticles, sustained-release formulations). He is the author of more than 130 international communications and 53 patent families.